Blood advances最新文献

{"title":"Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.","authors":"Takashi Nagayama, Shin-Ichiro Fujiwara, Satoshi Nishiwaki, Fumiya Wada, Naoyuki Uchida, Masatsugu Tanaka, Mamiko Sakata-Yanagimoto, Makoto Onizuka, Kazuya Ishiwata, Yuta Hasegawa, Shuichi Ota, Noriko Doki, Hirohisa Nakamae, Tetsuya Nishida, Toshiro Kawakita, Masashi Sawa, Masahito Tokunaga, Fumihiko Ishimaru, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Hideki Nakasone","doi":"10.1182/bloodadvances.2024014938","DOIUrl":"10.1182/bloodadvances.2024014938","url":null,"abstract":"<p><strong>Abstract: </strong>Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when HLA-matched donors are not available. Using Japanese registry data, we evaluated the impact of haploidentical donor age on posttransplant outcomes by comparing PTCY-haplo and CBT. We analyzed data for 5161 patients aged 16 to 70 years who received their first HSCT for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia. Haploidentical donors were categorized as \"younger\" (aged <40 years) or \"older\" (aged ≥40 years), and the patients were divided into younger (aged <50 years) and older (aged ≥50 years) cohorts. In the older cohort, PTCY-haplo from younger donors had better overall survival (OS; 55.5% vs 50.8%, P = .006), lower nonrelapse mortality (NRM; 17.3% vs 28.6%, P < .001), and higher relapse rates (33.0% vs 24.9%, P = .017) than with CBT. PTCY-haplo from older donors had comparable OS (44.1% vs 50.8%, P = 1.00), NRM (27.3% vs 28.6%, P = 1.00), and relapse (29.2% vs 24.9%, P = .90) to that with CBT. In the younger cohort, PTCY-haplo from younger and older donors showed OS, NRM, and relapse comparable with CBT. In the older cohort, cumulative incidence of acute graft-versus-host disease (GVHD) was higher with CBT than with PTCY-haplo, regardless of donor age. However, in the younger cohort, acute GVHD was lower in PTCY-haplo from younger donors than with CBT. PTCY-haplo from younger donors to older patients offers better clinical outcomes than CBT.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3226-3237"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we harmonize classification of TP53 mutant MDS/AML?","authors":"David A Sallman","doi":"10.1182/bloodadvances.2025016336","DOIUrl":"10.1182/bloodadvances.2025016336","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":"9 13","pages":"3381-3382"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups.","authors":"Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, Karsten Spiekermann","doi":"10.1182/bloodadvances.2024014570","DOIUrl":"10.1182/bloodadvances.2024014570","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3336-3339"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era.","authors":"Pontus Hedberg, Lisa Blixt, Sandra Eketorp Sylvan, Isabela Killander Möller, Hannes Lindahl, Fredrik Kahn, Åsa Nilsdotter-Augustinsson, Mats Fredrikson, Sofia Nyström, Peter Bergman, Christina Carlander, Soo Aleman, Pontus Nauclér, Anders Österborg, Lotta Hansson","doi":"10.1182/bloodadvances.2024015260","DOIUrl":"10.1182/bloodadvances.2024015260","url":null,"abstract":"<p><strong>Abstract: </strong>Individuals with chronic lymphocytic leukemia (CLL) face an increased risk for severe COVID-19. This study from Sweden, a country that only had a few mandatory restrictions at the onset of the pandemic, used 10 nationwide registers to compare the risks for severe COVID-19 outcomes of polymerase chain reaction-verified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections through February 2023 in individuals with and those without CLL. From a population of 8 275 839 (6653 CLL) individuals born between 1930 and 2003, 2 088 163 first infections (1289 CLL) were included. The 90-day all-cause mortality rate and adjusted relative risk (aRR; 95% confidence interval) for individuals with CLL vs the general population was 24.8% (1.95; 1.58-2.41) during wild-type, 17.2% (2.38; 1.58-3.57) during Alpha, 4.1% (0.71; 0.24-2.08) during Delta, and 12.6% (1.49; 1.24-1.78) during Omicron infections. Their mortality during Omicron was 0.6% (<65 years), 5.4% (65-74 years), and 19.7% (≥75 years). Small molecule inhibitors (1.56; 1.03-2.37) and corticosteroid usage (1.45; 1.04-2.02) was associated with increased mortality. Next, we analyzed the all-cause mortality in the capital (Stockholm), widely affected by SARS-CoV-2 at the onset of the pandemic. Mortality in individuals with CLL increased by 55% during the first 6 months of 2020 vs 2019, and the age- and sex-aRR by 30 June was 1.53 (1.09-2.15) for individuals with CLL (P = .02) and 1.29 (1.25-1.33) for the general population (P < .001). Collectively, a significantly increased risk for severe COVID-19 and death was observed among individuals with CLL in Sweden, particularly at the onset of the pandemic when few national protective measures were introduced and also after Omicron emerged, emphasizing the need for a more pro-active pandemic strategy for CLL.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3170-3181"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study.","authors":"Emily Sirotich, Saifur R Chowdhury, Dimpy Modi, Gordon Guyatt, Melanie St John, Kerolos Eisa, Adam Cuker, Carolyn E Beck, Rachael F Grace, Justin W Yan, Shuoyan Ning, Charles T Quinn, Amanda Pfeiffer, Michele P Lambert, Karen Panckeri, Allyson Pishko, Kristine VanAarsen, Ahmed Slim, Kathryn Carrier, Rebecca Geer, Abinaya Arulselvan, Matthew Basara, Brenna Cannon, Ellis J Bloom, Sam J King, Daya Gill, Laura M Venier, Emily Xu, Ishaq Siddiqui, Bonnie Liu, Timothy Mercier, Taylah Buissereth, Emily M Harris, Enass H Raffa, Joel Livingston, Mahmudur Rahman Chowdhury, Maryam Akbari-Moghaddam, Dongyoung Kim, Lehana Thabane, Dena Zeraatkar, Donald M Arnold","doi":"10.1182/bloodadvances.2024015494","DOIUrl":"10.1182/bloodadvances.2024015494","url":null,"abstract":"<p><strong>Abstract: </strong>Critical bleeding in patients with immune thrombocytopenia (ITP) is a life-threatening hematologic emergency. This study aimed to describe the frequency, management, and outcomes of critical bleeds among adults and children with ITP. We conducted a retrospective cohort study of patients with ITP who presented to the emergency room with a platelet count <20 × 109/L across 7 centers in the United States and Canada between 2010 and 2019. Of 1226 patients (n = 296 adults; n = 930 children), 28 (2.3%) had critical bleeds (adults, n = 15 [median age, 68 years]; children, n = 13 [median age, 11 years]). Of patients with critical bleeds, 12 adults (80.0%) and 6 children (46.2%) had intracranial hemorrhage (ICH). For adults, the common interventions used to treat critical bleeds were platelet transfusions (n = 11 [73.3%]), corticosteroids (n = 10 [66.7%]), and IV immunoglobulin (n = 8 [53.3%]), and for children, common interventions were IV immunoglobulin (n = 10 [76.9%]), corticosteroids (n = 8 [61.5%]), platelet transfusions (n = 8 [61.5%]), thrombopoietin receptor agonists (n = 4 [30.8%]), and antifibrinolytic agents (n = 4 [30.8%]). For both adults and children, the most common treatment combination was corticosteroids, IV immunoglobulin, and platelet transfusion (n = 6 [40.0%] vs n = 6 [46.2%]). The median time from presentation to first treatment was 6.9 hours for adults and 3.5 hours for children. Overall, 9 patients (32.1%) with critical ITP bleeds died, including 7 adults (46.7%) and 2 children (15.4%). Critical bleeding in patients with ITP was rare but frequently fatal, especially among older adults with ICH and when treatments were delayed.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3238-3248"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complement C5 inhibition in early onset HELLP syndrome.","authors":"Gloria F Gerber, Robert A Brodsky, Arthur Jason Vaught","doi":"10.1182/bloodadvances.2024014746","DOIUrl":"10.1182/bloodadvances.2024014746","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3304-3307"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia.","authors":"Ashvind Prabahran, Liangliang Wu, Ash Lee Manley, Zhijie Wu, Shouguo Gao, Hiroki Mizumaki, Valentina Baena, Zulfeqhar Syed, Christian A Combs, Jichun Chen, Xingmin Feng, Neal S Young","doi":"10.1182/bloodadvances.2024015621","DOIUrl":"10.1182/bloodadvances.2024015621","url":null,"abstract":"<p><strong>Abstract: </strong>Megakaryocytes (MKs) serve diverse roles beyond platelet production, including hematopoietic stem cell maintenance and immune response modulation. In our mouse model of immune bone marrow failure (BMF), we observed the unexpected persistence of MKs despite thrombocytopenia. These MKs exhibited heightened expression of immune activation markers, such as IA-IE and CD53, compared with MKs from healthy controls. Single-cell RNA sequencing analysis (scRNA-seq) revealed upregulation of immune response pathways and downregulation of pathways related to platelet function and homeostasis in MKs from animals with marrow failure (BMF). Electron microscopy demonstrated that these MKs had fewer cytoplasmic extensions, reduced α-granules, and a less developed demarcation membrane system. MKs from BMF animals had reduced ability to produce platelets compared with normal control MKs. Interestingly, when cocultured with BMF-derived T cells, MKs from healthy mice acquired immune characteristics. Functionally, MKs from BMF mice suppressed hematopoietic stem cell colony formation in coculture experiments. Mechanistically, these MKs appeared to act as antigen-presenting cells, capable of T-cell activation. Notably, similar immune activation of MKs was observed in patients with aplastic anemia through scRNA-seq. These findings highlight the immune functions of mature MKs in an alloimmune model of BMF, with potential implications for human aplastic anemia and related hematologic disorders.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3315-3330"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.","authors":"Leyre Bento, Antonio Gutiérrez, Carmen Martínez, María Consejo Ortí Verdet, Marina Sorribes, Ana Carolina Caballero, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Bastos-Oreiro, Paula Fernández Caldas-González, Belén Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago, Fernando Martín-Moro, Lucía García, Pilar Gómez, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González, Pedro González, Cristina Blázquez, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero, Alejandro Martín García-Sancho","doi":"10.1182/bloodadvances.2024015415","DOIUrl":"10.1182/bloodadvances.2024015415","url":null,"abstract":"<p><strong>Abstract: </strong>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3281-3292"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.","authors":"Ajay K Gopal, Philippe Armand, Sattva S Neelapu, Nancy L Bartlett, Stephen E Spurgeon, John Kuruvilla, Kerry J Savage, John P Leonard, Arnold B Gelb, Nasir Ahmed, Shiqi Dong, Sai Praneeth Bathena, Rasika Suryawanshi, Jenny Qun Wu, Sheen Wang, Douglas E Gladstone","doi":"10.1182/bloodadvances.2024015086","DOIUrl":"10.1182/bloodadvances.2024015086","url":null,"abstract":"<p><strong>Abstract: </strong>Despite high response rates, anti-programmed death 1 (anti-PD-1) monotherapy eventually fails in most patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) and is ineffective in most other B-cell malignancies. The lymphocyte activation gene 3 (LAG-3) cell-surface receptor represents another immune checkpoint that can be targeted to induce remissions in these diseases; dual inhibition of PD-1 and LAG-3 is approved in advanced melanoma. We performed a multicenter phase 1/2a open-label study of the anti-LAG-3 antibody relatlimab (RELATIVITY-022) administered as monotherapy or in combination with nivolumab in patients with R/R B-cell malignancies. We treated 106 patients and no dose-limiting toxicities were observed during escalation. The recommended phase 2 dose was relatlimab 240 mg as monotherapy or nivolumab 240 mg plus relatlimab 160 mg, administered every 2 weeks. No unexpected safety signals were observed compared with anti-PD-1 monotherapy. In the HL expansion cohorts, objective response rate (ORR) was 62% and complete response rate (CRR) was 19% in anti-PD-1/anti-programmed death ligand 1 (anti-PD-[L]1)-naive patients (n = 21), with a median progression-free survival (PFS) of 19 months; ORR was 15% and CRR 0%, with median PFS of 6 months in anti-PD-(L)1-progressed patients (n = 20). In diffuse large B-cell lymphoma, ORR was 7% with no CRs (n = 15), and median PFS was 2 months. Nivolumab plus relatlimab appeared to be safe and tolerable. Responses in patients with anti-PD-(L)1-naive HL was encouraging, although the contribution of relatlimab to overall efficacy of the combination needs to be further evaluated. This trial was registered at www.ClinicalTrials.gov as #NCT02061761.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3383-3394"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 and CLL in Sweden: lessons learned?","authors":"Stephen P Mulligan","doi":"10.1182/bloodadvances.2025016266","DOIUrl":"10.1182/bloodadvances.2025016266","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":"9 13","pages":"3223-3225"},"PeriodicalIF":7.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}